GlassScriptPhysician profile
Kerry Keaffaber
NPI 1740226307
$1,818.73
in general payments reported to CMS, 2019-2025
25 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $251 · 2021: $371 · 2022: $163 · 2023: $104 · 2024: $415 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.74 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $301.00 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $280.51 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Janssen Pharmaceuticals, INC | $186.17 | 2019-2021 | |
| Lundbeck LLC | $161.08 | 2024-2025 | Vyepti, Rexulti |
| Pfizer INC. | $155.87 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.70 | 2020-2025 | Jardiance |
| Mylan Specialty L.P. | $76.90 | 2024 | Yupelri |
| Amgen INC. | $72.97 | 2019-2024 | Evenity |
| Exact Sciences Corporation | $69.45 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $54.49 | 2021-2024 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $46.99 | 2024-2025 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $33.55 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.89 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $31.76 | 2019-2020 | |
| Braintree Laboratories, INC. | $26.97 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $26.16 | 2020-2022 | |
| Nevro Corp. | $21.82 | 2024 | Senza |
| Abbvie INC. | $20.52 | 2025 | |
| Sanofi Pasteur INC. | $19.01 | 2022 | |
| Radius Health, INC. | $18.23 | 2020 | |
| Sumitomo Pharma America, INC. | $17.96 | 2023 | Gemtesa |
| Merck Sharp & Dohme LLC | $15.24 | 2021 | |
| Eisai INC. | $14.12 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.97 | 2022 | |
| Allergan, INC. | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Keaffaber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.